Clinical Trials Browser

INDUSTRY × Myeloproliferative Disorders × imetelstat × Clear all

NCT04576156 2025-12-04

A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment

Phase 3 Active not recruiting

Myeloproliferative Disorders, Polycythemia, Thrombocytosis, Primary Myelofibrosis

NCT01731951 2021-09-21

Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis

Phase 2 Completed

80 enrolled 31 charts

Myelodysplastic Syndromes, Myeloproliferative Disorders, Primary Myelofibrosis